Retatrutide (24 mg)

What is Retatrutide (24 mg)?

Retatrutide (24 mg) is a synthetic, long-chain peptide used in metabolic and endocrine research. It is designed to act on multiple receptor systems that regulate metabolic processes. Specifically, Retatrutide functions as a triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.

This multi-pathway approach enables researchers to study how the coordinated activation of incretin and glucagon pathways influences glucose metabolism, lipid utilization, appetite regulation, and overall energy balance in controlled laboratory settings.

The 24 mg format is ideal for extended experimental protocols, large-scale assays, and receptor-binding studies that require consistent peptide availability. All applications are for laboratory and preclinical research use only and are not intended for therapeutic or diagnostic purposes.

Product Specifications

• CAS Number: 2381089-83-2
• Synonyms: Retatrutide acetate, LY3437943
• Peptide Sequence:
  Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (Sodium salt)
• Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
• Molecular Weight: 4731.33 g/mol
• Subcategory: 
• Purity: ≥95% (verified by HPLC and mass spectrometry)
• Packaging Format: 24 mg lyophilized powder in sealed research-grade vial
• Storage Conditions: Store at 2–8 °C (≤–20 °C for periods of non-use). Protect from light.
• Intended Use: For Laboratory Research Use Only

Key Characteristics of Retatrutide (24 mg)

• Triple Receptor Activation (Research Context): Engineered to activate GLP-1, GIP, and glucagon receptors in experimental systems.
• Multi-Pathway Investigation: Facilitates research into the integration of metabolic signaling pathways.
• Stability-Enhanced Structure: Incorporates structural modifications, such as Aib residues and lipidation elements, to improve peptide stability in research environments.
• High Molecular Complexity: The long peptide chain enables the study of prolonged receptor interactions and downstream signaling effects.
• High Analytical Purity: Typically ≥95%, confirmed via chromatographic and spectrometric techniques.
• Lyophilized Presentation: Freeze-dried format preserves structural integrity and allows for controlled reconstitution.
• Research-Grade Manufacturing: Produced under standardized conditions to ensure reproducibility across research studies.

How Retatrutide (24 mg) Supports Research

Retatrutide (24 mg) is employed in research to investigate how coordinated receptor activation influences metabolic processes. By activating GLP-1, GIP, and glucagon receptors simultaneously, researchers can study receptor cross-talk, hormone signaling cascades, and the downstream cellular effects that contribute to metabolic regulation.
In laboratory models, Retatrutide is used to explore:

• Glucose metabolism and insulin signaling
• Lipid metabolism pathways
• Hormonal feedback mechanisms
• Energy expenditure and substrate utilization
• Multi-receptor agonist interactions

Retatrutide’s design allows for comparisons between single-pathway and multi-pathway activation in controlled research environments.

Research Applications & Usage Information

Retatrutide (24 mg) is commonly used in laboratory and preclinical research involving:

• GLP-1 receptor signaling assays
• GIP receptor pathway evaluation
• Glucagon receptor activation studies
• Endocrine and metabolic systems modeling
• Multi-receptor agonist comparison research
• Cellular second-messenger signaling analysis
• In vitro and animal-based metabolic research models

All applications are investigational and confined to controlled laboratory settings.

Handling and Storage Recommendations

• Store unopened vials at 2–8 °C. For extended preservation, maintain at ≤–20 °C. Protect from light.
• Keep vial sealed until ready for reconstitution.
• Minimize exposure to moisture and direct light.
• Allow vial to equilibrate before opening to reduce condensation.
• After reconstitution, store solutions at 2–8 °C according to laboratory protocol.
• Avoid repeated freeze–thaw cycles to maintain peptide stability.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013
2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
3. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2
4. Ma J, Hu X, Zhang W, Tao M, Wang M, Lu W. Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice. Endocrine. 2025;87(1):159-169. doi:10.1007/s12020-024-03998-8